Author:
Giuliani Luigi,Pezzella Pasquale,Giordano Giulia Maria,Fazio Leonardo,Mucci Armida,Perrottelli Andrea,Blasi Giuseppe,Amore Mario,Rocca Paola,Rossi Alessandro,Bertolino Alessandro,Galderisi Silvana,Maj Mario
Abstract
BackgroundThe development of neuroimaging biomarkers in patients with schizophrenia (SCZ) requires a refined clinical characterization. A limitation of the neuroimaging literature is the partial uptake of progress in characterizing disease-related features, particularly negative symptoms (NS) and cognitive impairment (CI). In the present study, we assessed NS and CI using up-to-date instruments and investigated the associations of abnormalities in brain resting-state (rs)-activity with disease-related features.MethodsSixty-two community-dwelling SCZ subjects participated in the study. Multiple regression analyses were performed with the rs-activity of nine regions of interest as dependent variables and disease-related features as explanatory variables.ResultsAttention/vigilance deficits were negatively associated with dorsal anterior cingulate rs-activity and, together with depression, were positively associated with right dorsolateral prefrontal cortex rs-activity. These deficits and impairment of Reasoning/problem-solving, together with conceptual disorganization, were associated with right inferior parietal lobule and temporal parietal junction rs-activity. Independent of other features, the NS Expressive Deficit domain was associated with the left ventral caudate, while the Motivational Deficit was associated with the dorsal caudate rs-activity.ConclusionNeurocognitive deficits and the two negative symptom domains are associated with different neural markers. Replications of these findings could foster the identification of clinically actionable biomarkers of poor functional outcomes.
Funder
Ministero dell’Istruzione, dell’Università e della Ricerca
Reference138 articles.
1. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016;Lancet,2017
2. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors;Correll;World Psychiatry,2022
3. Subjectivity, psychosis and the science of psychiatry;Sass;World Psychiatry,2022
4. What’s in the name “schizophrenia”? A clinical, research and lived experience perspective;Mesholam-Gately;World Psychiatry,2023
5. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis;McCutcheon;World Psychiatry,2022